Expertise in
16
conditions

Dr. Maurizio R. Zangari

Hematology
Uams Sats Program
4301 W Markham St, 
Little Rock, AR 
Accepting New Patients
Offers Telehealth
Expertise in
16
conditions
Uams Sats Program
4301 W Markham St, 
Little Rock, AR 

Overview

Maurizio Zangari is a Hematologist practicing medicine in Little Rock, Arkansas.

Dr. Zangari is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 131 peer reviewed articles and participating in 7 clinical trials. Dr. Zangari is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in AR

Hospital Affiliations

University Of Arkansas Medical Sciences
Fmol Health St Francis

Languages Spoken

English
Italian

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Arkansas Health and Wellness
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
HMO Partners
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
QualChoice
  • MEDICARE MAPD
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Uams Sats Program
4301 W Markham St, Little Rock, AR 72205

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3)
Enrollment Status: Active_not_recruiting
Publish Date: May 22, 2026
Intervention Type: Drug
Study Drugs: M-VTD-PACE, TT3-LITE Regimen (L-TT3)
Study Phase: Phase 3
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
UARK 2008-03 Phase II Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy (No Prior Transplant)
Enrollment Status: Active_not_recruiting
Publish Date: May 11, 2026
Intervention Type: Drug
Study Drugs: Melphalan, Velcade, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Study Phase: Phase 2
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Drug, Device
Study Drug: MEL-CFZ-TD-PACE
Study Phase: Phase 2
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes
Enrollment Status: Completed
Publish Date: October 15, 2019
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
UARK 2010-35, A Phase II Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 19, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients
A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients
Enrollment Status: Withdrawn
Publish Date: January 23, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

131 Total Publications

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients.
Journal: Blood cancer journal
Published: August 07, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Expertise in
9
conditions
Dr. Sharmilan Thanendrarajan
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-526-6990
Languages Spoken:
English, German
See accepted insurances
Offers Telehealth

Sharmilan Thanendrarajan is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Thanendrarajan is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-526-2873
Languages Spoken:
English, German
See accepted insurances
Accepting New Patients
Offers Telehealth

Carolina Schinke is a Hematologist practicing medicine in Little Rock, Arkansas. Dr. Schinke is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant. Dr. Schinke is currently accepting new patients.

Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Expertise in
7
conditions
Dr. Jason E. Farrar
Hematology | Oncology
Referral may be required

Uams Sats Program

4301 W Markham St, 
Little Rock, AR 
 (0.1 miles away)
501-686-5140
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jason Farrar is a Hematologist and an Oncologist practicing medicine in Little Rock, Arkansas. Dr. Farrar is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Pure Red Cell Aplasia, Aplastic Anemia, Childhood Acute Myeloid Leukemia, and Transient Erythroblastopenia of Childhood. Dr. Farrar is currently accepting new patients.

Frequently Asked Questions about Dr. Maurizio R. Zangari

How do I make an appointment with Dr. Maurizio R. Zangari?

You can book an appointment with Dr. Maurizio R. Zangari by calling their office at 501-686-8230. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Maurizio R. Zangari a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Maurizio R. Zangari is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Maurizio R. Zangari specialize in?

While Dr. Maurizio R. Zangari is a Hematology, they have specific expertise in Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Maurizio R. Zangari participate in research or clinical trials?

Yes. Dr. Maurizio R. Zangari has published 131 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Maurizio R. Zangari's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Maurizio R. Zangari accept my insurance?

Dr. Maurizio R. Zangari accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 501-686-8230 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zangari's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 23 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile